 Home > Chemicals Industry > China Chemical > Biopharmaceutical equipment ushered in a new opportunity, and the national substitute space has been opened

Biopharmaceutical equipment ushered in a new opportunity, and the national substitute space has been opened

 Last Update: 2021-08-10
 Source: Internet
 Author: User

Tags

acetone stainless steel

sponge circulatory system

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

[ Focus on Chemical Machinery Equipment Network ] In recent years, under the background of the rapid rise of Biotech and the expansion of the CDMO industry, biopharmaceutical equipment is ushering in a new opportunity for development.
The industry believes that the space for national replacement of biopharmaceutical equipment has been opened.
Domestically-made pharmaceutical machinery companies with a layout, certain R&D strength and rich products are expected to demonstrate their competitive advantages and gain new room for growth
.

Chemical machinery and equipment network hotspots pay attention to chemical machinery and equipment

With rapid downstream growth, biopharmaceutical equipment ushered in new opportunities

In recent years, with the growth of domestic biopharmaceutical companies' R&D investment and the promotion of a series of policies to encourage new drug R&D, Biotech listed companies have continued to rise
.
Statistics show that in 2020, the number of Biotech companies in China will be 865 (including listed and unlisted), accounting for 14% of the global total
.
The industry predicts that the proportion of China's Biotech companies will increase to 25%-30% in the next five years
.

As emerging Biotech companies generally lack their own production capacity, in order to reduce the cost of new drug development, these companies often choose to outsource a large proportion of their production operations
.
The role of CDMO companies is to help customers develop innovative drugs and improve related processes, continue to provide customers with small-batch or commercial production, and even help go public.
Pharmaceutical companies choose to cooperate with CDMO companies, which can greatly reduce costs
.

At present, the domestic CDMO industry is in a stage of rapid growth
.
With the continuous improvement of the technical level of China's CDMO industry, the quality system continues to be in line with international standards, and the global industrial chain (orders) is shifting domestically
.
At the same time, China is accelerating the reform of the medical system in recent years
.
In particular, China’s "Pharmaceutical Marketing Authorization Holder System Pilot Program" issued on June 6, 2016 proposed to allow drug R&D institutions or scientific researchers to submit drug clinical trial applications and drug marketing applications as drug registration applicants, and the applicant obtains Those who have a drug marketing license and a drug approval number can become a drug marketing license holder, and drug production can be entrusted to a manufacturing enterprise
.
This program has further promoted the rapid development of China's CDMO industry
.

　　According to Frost & Sullivan data, the compound growth rate of the domestic CDMO industry from 2019 to 2021 is approaching 20%, which is higher than the 12% growth rate overseas in the same period
.
The industry predicts that by 2024, the market size of China's CDMO industry will exceed the 100 billion mark, reaching 104.
88 billion yuan
.

　　It is worth mentioning that CDMO is an asset-heavy industry that requires high capital investment, and subsequent capital investment is needed to expand production capacity.
In the context of the rapid development of the CDMO industry and continuous expansion of production capacity, the industry generally believes that upstream biopharmaceutical equipment The industry has also ushered in new opportunities
.

　　The national space for biopharmaceutical equipment has opened

　　It is understood that the biopharmaceutical process will involve separation, liquid preparation, inactivation, liquid storage and other links.
The types of biopharmaceutical equipment used are also relatively rich.
With the rapid development of the CDMO industry, the long-term demand for related equipment will be Very broad
.
But for a long time, China's biopharmaceutical equipment mainly relied on imports, and the localization rate was low
.

　　The industry believes that since 2020, due to delays in delivery of imported equipment and other reasons, the space for national replacement of biopharmaceutical equipment has been opened.
Domestic pharmaceutical companies with early layout in this field and with certain R&D strength and rich products are expected Reflect the competitive advantage and gain new growth space
.

　　For example, Guosheng Securities issued a research report on July 7 and stated that it maintains the buy rating of Tofflon
.
The bank believes that Tofflon began to deploy product research and development in 2015, and its research and development progress and product richness are ahead of domestic ones.
It has products such as cryopreservation systems, shakers, wave reactors , stainless steel reactors, and separation and purification systems.
In the big wave of domestic substitution of biopharmaceutical equipment, it is expected to occupy a higher market share, enter a new life cycle, and open up a new round of upside; Dongxing Securities issued a research report on June 27, giving Chutian Technology a strong recommendation rating
.
The bank also believes that the localization of biopharmaceutical equipment can be expected, and the structure of the pharmaceutical equipment industry will be optimized
.

Reactor pharmaceutical equipment

　　Original title: Biopharmaceutical equipment ushered in a new opportunity, and the national substitute space has been opened

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.